Literature DB >> 1893497

Synthesis and antiestrogenic activity of the compounds related to the metabolites of (E)-4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]- 2-(4-isopropylphenyl)-1-butenyl]phenyl monophosphate (TAT-59) [corrected].

K Ogawa1, Y Matsushita, I Yamawaki, M Kaneda, J Shibata, T Toko, T Asao.   

Abstract

The metabolites of (E) [corrected]-4-[1-[4-[2-dimethylamino)ethoxy]phenyl]- 2-(4-isopropylphenyl)-1-butenyl]phenyl monophosphate, TAT-59, (1), a potent antitumor agent for hormone-dependent tumors, and derivatives of TAT-59 were synthesized to confirm its proposed structure. The structure and the Z-configuration of the metabolites (2a-8a) were confirmed by comparison with synthesized authentic compounds. All of the metabolites and the derivatives of TAT-59 were tested for a binding affinity toward estrogenic receptors in vitro and antiuterotrophic activity in vivo. Most of the metabolites possessed remarkable binding affinity toward estrogenic receptors as well as fairly good antiuterotrophic activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1893497     DOI: 10.1248/cpb.39.911

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  2 in total

1.  Characterization of the isomeric configuration and impurities of (Z)-endoxifen by 2D NMR, high resolution LC⬜MS, and quantitative HPLC analysis.

Authors:  Phyllis Elkins; Donna Coleman; Jason Burgess; Michael Gardner; John Hines; Brendan Scott; Michelle Kroenke; Jami Larson; Melissa Lightner; Gregory Turner; Jonathan White; Paul Liu
Journal:  J Pharm Biomed Anal       Date:  2013-07-24       Impact factor: 3.935

2.  Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma.

Authors:  T Toko; J Shibata; Y Sugimoto; H Yamaya; M Yoshida; K Ogawa; E Matsushima
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.